When you can't buy growth, engineer it.
Ad restrictions don't have to cap you. We build the retention, predictive-LTV and organic-content engine that compounds — with compliance baked in.
One policy flag should not kill your growth.
The ad account is a single point of failure
Supplements, peptides and telehealth get flagged, disapproved and banned. Building a growth model on top of an account that can vanish is a bet, not a plan.
Acquisition is fragile and expensive
You cannot scale on paid alone when paid is conditional. Every restriction pushes CAC up and optionality down.
LTV is a guess
Retention is the entire game in this category, and the email and SMS carrying it is usually basic while the LTV number underneath it is a hunch.
Compliant content at volume is hard
Organic and short-form is where the growth is, and producing enough of it without tripping a claims problem is the constraint nobody solves.
Claims risk sits on every asset
FTC and FDA-adjacent language turns each piece of copy into a review cycle, which is exactly what kills publishing cadence.
Build the channels that survive the ban.
Assume restriction as the starting condition, then build the engine that does not depend on ad approval.
Lifecycle carries the revenue when paid is constrained. Predictive LTV and churn models decide where retention spend goes, and the subscription flows are built against the prediction rather than a flat rule.
On top of that, an organic engine: AI-assisted content plus short-form video shot and edited in-house, and an AI-search presence that gets you recommended for health questions no ad account can be banned from.
The stack, mapped to the restriction.
Results, published.
Most agencies live and die by the ad account. We build the channels that outlast it.
Restriction is the design input here, not the surprise.
On-vertical proof
Science in Sport and Gold Collagen are supplements and beauty, not analogies borrowed from another category.
Retention at partner level
Klaviyo partners. The flows are rebuilt against predicted LTV rather than a send calendar.
Video in-house
Short-form is shot and edited by our own team, which is the only way compliant volume stays affordable.
The questions you were going to ask.
Agencies keep getting our accounts banned.
Our email is 'good enough'.
Can you handle compliant claims?
Do you handle peptides and telehealth specifically?
Which retention platform do you work in?
Do you actually produce the video?
Run the numbers yourself.
See what your lifecycle is actually worth. Both are free.
Let's grow.
EGGKNITE© 2026 ALL RIGHTS RESERVED — A VERTEX INNOVATION COLLECTIVE COMPANY